IL2 and melanoma: This study seeks to address these gaps by providing real-world longitudinal data on serum TNF-α, IL-2, and IL-10 dynamics in a cohort of patients with stage IV NSCLC and melanoma undergoing anti-PD-1 therapy with Nivolumab.